GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (FRA:4OR1) » Definitions » Notes Receivable

Organovo Holdings (FRA:4OR1) Notes Receivable : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Organovo Holdings Notes Receivable?

Organovo Holdings's Notes Receivable for the quarter that ended in Sep. 2024 was €0.00 Mil.


Organovo Holdings Notes Receivable Historical Data

The historical data trend for Organovo Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organovo Holdings Notes Receivable Chart

Organovo Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Organovo Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Organovo Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Organovo Holdings Notes Receivable Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Organovo Holdings Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.

Organovo Holdings Headlines

No Headlines